The benefits and harm of psychedelics in the treatment of patients with mental health and substance abuse disorders: an integrative literature review
Abstract
The purpose of the study was to describe the benefits and harm of using psychedelics in the treatment of patients with mental health and substance abuse disorders. The study focused on classic psychedelics, specifically psilocybin and LSD. The study was carried out as an integrative literature review and the data was sought using Medic, Cinahl, PubMed MEDLINE and PsycINFO databases. A total of 12 scientific studies were selected for the literature review, and the data was analyzed using an inductive content analysis method. The results of the study indicated that psychedelics can be used to treat patients with mental health and substance abuse disorders very effectively. Key mental health disorders that can be treated include treatment-resistant depression, self-harm, anxiety disorder, and the depressive phase of bipolar disorder. LSD and psilocybin helped effectively and quickly. Psychedelics increase plasticity and cognitive flexibility in the brain. However, it should be remembered that there is also some harm with the use of psychedelics. The harm occurs specifically outside the clinical research environment, where the use of psychedelics is linked to crime, spontaneous recreational use, and the simultaneous use of other intoxicants together with psychedelics. Preliminary research results indicate that psychedelics help effectively, quickly and provide long-term treatment responses in patients with mental health and substance abuse disorders. Additional clinical trials will be needed. The selection of different patient groups and the size of treatment doses should also be tested. Regulatory barriers should be lifted to allow clinical testing of psychedelic-assisted therapies. From the perspective of the global economy, it would be important to treat mental health and substance abuse disorders effectively and with permanent treatment results.
Downloads
References
2. Al-Naggar, R., A., Alshaikhli, H. & Erlam, G. (2021). Effectiveness of Psilocybin on Depression: A Qualitative Study. Electronic Journal of General Medicine, 18(3), 1–7.
3. Bogenschutz, M., P., Forcehimes, A., A., Pommy, J., A., Wilcox, C., E., Bar-bosa, P., C., R. & Strassman, R., J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of psychopharmacology, 3, 289–299.
4. Carhart-Harris, R., L., Bolstridge, M., Day, C., M., J., Rucker, J., Watts, R., Erritzoe, D., E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J., A., Forbes, B., Feilding, A., Taylor, D., Curran, H., V. & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 235(2), 399–408.
5. DellaCrosse, M., Pleet, M., Morton, E., Ashtari, A., Sakai, K., Woolley, J. & Michalak, E. (2022). "A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. PloS one, 17 (12).
6. Doss, M., K., Považan, M. Rosenberg, M., D., Sepeda, N., D., Davis, A., K., Finan, P., H., Smith, G., S., Pekar, J., J., Barker, P., B., Griffiths, R., R. & Barrett, F., S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational psychiatry, 11 (1), 574.
7. Fauvel, B., Strika-Bruneau, L. & Piolino, P. (2021). Changes in self-rumination and self-compassion mediate the effect of psychedelic experiences on decreases in depression, anxiety, and stress. US, Educational Publishing Foundation.
8. Griffiths, R., R., Richards, W., A., McCann, U. & Jesse, R. (2006). Psilocybin can occasion mystical type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology Berl, 3, 268–283.
9. Holze, F., Gasser, P., Müller, F., Dolder, P. C. & Liechti, M. E. (2023). Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biological Psychiatry, 93, 215–223.
10. Holze, F., Caluori, T., V., Vizeli, P. & Liechti, M. E. (2022). Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology, 239 (6), 1893–1905.
11. Lea, T., Amada, N., Jungaberle, H., Schecke, H. & Klein, M. (2020). Microdosing psychedelics: Motivations, subjective effects and harm reduction. International Journal of Drug Policy, 75.
12. Nichols, D., E. (2016). Psychedelics. Pharmacol Rev. 2, 264–355.
13. Nichols, D., E. (2004). Hallucinogens. Science Direct. Pharmacology & Therapeutics 2, 131–181.
14. OECD (2023). Health at a Glance 2023. Available: https://www.oecd-ilibrary.org/doc)server/7a7afb35-en.pdf?expires=1700569106&id=id&accname=guest&checksum=3363EA1A67EF88114CD21A891DBEDA3F.
15. Raison, C., L., Jain, R., Penn, A., D., Cole, S., P. & Jain, S. (2022). Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations with Patterns of Use, Reported Harms, and Transformative Mental States. Frontiers in psychiatry, 13, 831092.
16. St. Arnaud, K., O. & Sharpe, D. (2022). Contextual parameters associated with positive and negative mental health in recreational psychedelic users. United Kingdom: Taylor & Francis.
17. Suomen Mielenterveys ry (2023). Tilastotietoa mielenterveydestä. Available https://mieli.fi/yhteiskunta/mielenterveys-suomessa/tilastotietoa-mielenterveydesta/.
18. Tupper, K., W., Wood, E., Yensen, R. & Johnson, M., W. (2015). Psychedelic medicine: a re-emerging therapeutic paradigm. CMAJ National Library of Medicine 14, 1054–1059.
19. Zeifman, R., J., Wagner, A., C., Monson, C., M. & Carhart-Harris, R., L. (2023). How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. Journal of affective disorders, 334, 100–112.
